Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial by LASHAY, Alireza et al.
 
 
Med Hypothesis Discov Innov Ophthalmol. 2016; 5(1)  
 
 
32 SAFFRON SUPPLEMENTATION IN AGE-RELATED MACULAR DEGENERATION 
Original Article 
             Medical Hypothesis, Discovery &Innovation 
Ophthalmology Journal 
 
 
 
Short-term Outcomes of Saffron Supplementation in Patients 
with Age-related Macular Degeneration: A Double-blind, 
Placebo-controlled, Randomized Trial 
Alireza LASHAY 1; Gholamreza SADOUGH 1; Elham ASHRAFI 1; Mohammadreza LASHAY 1; Morteza MOVASSAT 1; Shahin 
AKHONDZADEH 2 
 
1. Farabi Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran 
2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical sciences, Tehran, Iran 
 
ABSTRACT 
In modern pharmacological medicine, saffron is used for various purposes due to its antioxidant effect. This study evaluated 
retinal function after treatment with saffron supplementation during a follow-up period of 6 months to provide further 
insight into the efficacy and safety considerations of this treatment. Sixty patients with wet or dry age-related macular 
degeneration (AMD) were randomly assigned to receive oral saffron 30 mg/d or placebo supplementation for 6 months. 
Optical coherence tomography (OCT), electroretinography (ERG), fluorescein angiography, and visual acuity testing were 
performed at baseline and 3 and 6 months after treatment. The main outcome measures were OCT, ERG amplitude, and 
implicit time. Six months after treatment, no statistically significant decrease in OCT results was observed between the 
groups with dry AMD (P = 0.282). However, there was a statistically significant increase in ERG results between the groups at 
3 months after treatment (P = 0.027). In addition, there was a significant decrease in OCT results between groups with wet 
AMD at the follow-up (P = 0.05). Finally, there was a significant increase in ERG findings between the groups with wet AMD 
at 3 months after treatment (P = 0.01), but these changes decreased at 6 months after treatment (P = 0.213). Daily 
supplementation with 30 mg of saffron for 6 months may result in a mid-term, significant improvement in retinal function in 
patients with AMD. 
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Introduction 
In western countries, age-related macular degeneration 
(AMD) is the leading cause of visual impairment in people 
aged 55 years or older, (1-5) and the prevalence of this 
disease is expected to increase globally because of 
demographic and epidemiologic transitions (6-8). None 
of the current therapeutic strategies optimally improve 
visual acuity, especially in those with the neovascular 
form of AMD (8-12); moreover, results are usually 
unsatisfactory and require frequent retreatments (9-12). 
Although numerous medical and surgical modalities for 
AMD are under investigation, none have yet provided 
satisfactory effects regarding the development of 
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advanced AMD (13-17). The use of herbal drugs by 
patients has considerably increased in the past few 
decades, and physicians’ interest in these agents is 
increasing owing to the fewer side effects, better 
tolerability, and equal efficacy compared to conventional 
medications. Before such alternative therapies can be 
used ethically or effectively, however, it is crucial to 
examine traditional herbal compounds through the lens 
of modern scientific investigation. Crocus sativus L., 
commonly known as saffron, is a perennial stemless herb 
of the Iridaceae family that principally grows in 
Mediterranean countries, especially Iran (18). Modern 
pharmacological studies have demonstrated that saffron 
extract and its active constituents may have anti-tumor, 
radical scavenger, memory-enhancing, and hypolipidemic 
properties (18-22). Recent research has highlighted the 
importance of antioxidant therapy in preventing 
oxidative stress-induced neuronal damage, and it has 
been hypothesized that the saffron extract may be a 
useful treatment option for AMD because of its powerful 
antioxidant effects (23-25). In addition to its antioxidant 
and anti-inflammatory properties, studies have 
suggested that it may protect against retinal stress (26, 
27). Results from the Age-Related Eye Disease Study 
(AREDS) showed that antioxidant supplementation may 
prevent or lessen the development of AMD in any stage 
of the disease (28). Several potential antioxidants are not 
studied in current clinical trials; therefore, we decided to 
study the efficacy and safety of saffron supplementation 
with respect to retinal function and AMD treatment using 
a placebo-controlled, double-blind, randomized 
controlled trial. 
MATERIALS AND METHODS 
This randomized, double-blind, placebo-controlled study 
was approved by the Ethics Committee of the Eye 
Research Center at Farabi Eye Hospital and has been 
registered in the Iranian National Registry for Clinical 
Trials (IRCT 201205219820N1). Signed informed consent 
was obtained from all participants before enrolment. 
Thirty patients with dry AMD and 30 with wet AMD were 
recruited from the Retina Clinic at Farabi Eye Hospital 
between June 2011 and March 2012. Inclusion criteria 
were a minimum age of 65 years, a physical status class 
of I-II based on the American Society of 
Anaesthesiologists classification system, a clinical 
diagnosis of dry or wet AMD confirmed by fluorescein 
angiography, best corrected visual acuity between 
20/400 and 20/40 in the study eye, and clear optical 
media. Patients were excluded if they had cataracts, 
glaucoma, corneal opacities, any sign of retinal or optic 
nerve disease other than AMD, or systemic disease. A 
patient flowchart according to the CONSORT statement is 
summarized in Figure 1. 
All participants with wet AMD received monthly 
intravitreous bevacizumab (IVB) injections for 3 months 
according to the standard protocol of the American 
Academy of Ophthalmology (29). Patients were then 
randomly allocated to either the treatment group 
(saffron group) or the control group (placebo group) 
using computer-generated numbers in sealed envelopes. 
The saffron group received a daily dose of 2 oral saffron 
capsules (Saffro Mood), each containing 15 mg of saffron 
extract, donated by Green Plants of Life Co. (IMPIRAN; 
Tehran, Iran) for 6 months. Control patients received 
placebo capsules, shaped similarly to the saffron 
capsules, with the same dose and duration. Patients 
were not permitted to consume other nutrients or 
supplements that could affect outcome measures during 
the study period. Patient compliance was checked 
weekly by telephone. For all patients, optical coherence 
tomography (OCT), electroretinography (ERG), and 
fluorescein angiography (FA) were performed at baseline 
and at 3- and 6-month follow-up visits. Primary outcome 
measures were based on macular thickness and ERG 
amplitude values. During the entire course of the trial, no 
other systemic pharmacologic agents were administered. 
All examinations and assessments were performed by a 
single ophthalmologist. All individuals involved in the 
study, including those who administrated the 
medications and performed the examinations, as well as 
the enrolled patients, were blinded to the assigned 
treatment groups as each treatment group was referred 
to according to a binary code. 
 
Statistics 
Data were analyzed using SPSS software version 21. 
Quantitative data were analyzed using the student t-Test 
and are described as the mean ± SD. The effect of time 
was assessed using repeated measures analysis of 
variance (repeated measures ANOVA). A P-value < 0.05 
was considered statistically significant. 
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Figure 1. CONSORT 2010 flow diagram 
 
RESULTS
Of the 60 participants who initially enrolled, 40 patients 
completed the study: 21 patients in the saffron group (12 
patients with dry AMD and 9 with wet AMD) and 19 
patients in the placebo group (7 patients with dry AMD 
and 12 patients with wet AMD). The enrolled patients 
included 16 women and 24 men, and there were no 
significant gender differences between the saffron and 
placebo groups (P = 0.583). Mean age did not differ 
significantly between saffron and placebo groups for 
patients with dry AMD (68.4 ± 4.7 and 63.0 ± 6.8 years, 
respectively, P = 0.52) or wet AMD (66.8 ± 5.7 and 69.3 ± 
9.2 years, respectively, P = 0.56). Additionally, 7 patients 
were smokers and there was no significant inter-group 
difference in the number of smoking patients (P = 0.426). 
Table 1 summarizes our study findings in terms of 
macular thickness and ERG amplitude in each study 
group as well as the results of inter-group comparisons 
using independent t-tests and repeated measures 
ANOVA. Six months after treatment began, changes in 
macular thickness were significantly different between 
the saffron and placebo groups for patients with wet 
AMD (P = 0.05) but not those with dry AMD (P = 0.28). 
The trend for changes in macular thickness is illustrated 
in Figure 2. ERG amplitude changes were significantly 
different between the saffron and placebo groups at 3 
months in patients with dry AMD (P = 0.03) compared to 
wet AMD (P = 0.007), but these inter-group differences 
were no longer significant at 6 months (P = 0.12 and P = 
0.26, respectively). 
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Figure 2. Trend of changes in macular thickness (micron) from 
baseline to 6 months in the treatment (saffron) and control 
(placebo) groups of patients with dry and wet age-related 
macular degeneration (AMD). 
 
Figure 3 illustrates the trend for changes in ERG 
amplitude. According to the results of the repeated 
measures analysis, a significant effect between the 
saffron and placebo groups was only observed for ERG 
amplitude in patients with dry AMD (P = 0.05). No major 
side effects were observed among patients in either the 
saffron or the placebo group, and no patient reported 
severe complications, such as bleeding. 
 
Figure 3. Trend of changes in electroretinogram amplitude 
(Mvolt) from baseline to 6 months in the treatment (saffron) 
and control (placebo) groups of patients with dry and wet age-
related macular degeneration (AMD). 
 
Table 1. Inter-group comparisons of macular thickness (micron) and electroretinogram (ERG) amplitude (Mvolt) from baseline to 6 
months in the treatment (saffron) and control (placebo) groups of patients with dry and wet age-related macular degeneration (AMD). 
 Dry AMD Wet AMD 
 
Baseline 3 months 6 months 
P 
value* 
Baseline 3 months 6 months 
P 
value* 
Macular 
thickness  
   0.58    0.12 
Saffron group 
227.92 ± 
31.5 
228 ± 28.3 
225.64 ± 
30.3 
 
371.83 ± 
41.3 
283.87 ± 
4.3 
269.25 ± 
3.7 
 
Placebo 
group 
239.87 ± 
37.4 
231.6 ± 
24.6 
238.54 ± 
22.3  
381.55 ± 
48.5 
291.33 ± 
4.9 
228.47 ± 
8.9  
P value** 0.32 0.58 0.28 
 
0.49 0.84 0.05 
 
ERG 
amplitude 
   0.05    0.21 
Saffron group 100.68±31.3 
102.14 ± 
3.1 
102.9 ± 3.1  80.45 ± 3.5 
80.97 ± 
0.27 
81.53 ± 2.8  
Placebo 
group 
85.88 ± 35.4 89.8 ± 3.5 89.6 ± 3.5  76.38 ± 2.1 
79.92 ± 
0.21 
79.42 ± 2.1 
 
P value** 0.20 0.03 0.12  0.63 0.007 0.26  
* P value for the effect of time in the repeated measures analysis of variance; ** P value for group comparisons with independent t-tests. 
 
DISCUSSION
In this study, we demonstrated the efficacy of saffron 
supplementation for improving retinal function after 3 
months of daily treatment in patients with AMD. In 
addition, our results suggest that saffron 
supplementation, when combined with intravitreal 
bevacizumab, may significantly improve macular 
thickness in patients with wet AMD after 6 months of 
daily treatment. Our results are in agreement with other 
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studies with similar follow-up durations that showed a 
significant improvement in retinal function in association 
with antioxidant supplementation (30-35). In addition, 
the results of the present study may be confidently 
attributed to saffron supplementation since the 
distribution of known risk factors (i.e., smoking) was 
similar in both groups. In our study, ERG amplitude 
recordings were significantly increased in the saffron 
group after 3 months of treatment, but these changes 
were not significant at 6 months. According to other 
studies, (36-39) response to treatment in patients with 
retinal degenerative disease is often initially impressive 
but usually declines with time, so the results of our study 
are consistent with this trend. We can assume that the 
improvements in retinal function observed in this study 
are related to the activity of chemical components of 
saffron, specifically to the important role of crocin, and 
antioxidant derivatives of carotenoids. We hypothesize 
that the ERG changes observed in the present study 
indicate that mid-term saffron supplementation may 
reduce photoreceptor damage induced by chronic 
oxidative injury. (39-41). Based on existing hypotheses, 
these components have the potential to act as protective 
factors against oxidative damage for aging and AMD 
retinas, whose disease pathophysiology has been linked 
to light-induced oxidative damage to the outer retina (27, 
28, 40). 
In patients with WET type AMD, macular thickness 
decreased after 3 months and after 6 months in both the 
saffron and placebo groups. This reduction could be 
explained by the use of intravitreous bevacizumab (IVB), 
but these changes were significant in the saffron group, 
especially in the sixth month. The reason for this 
increased reduction in macular thickness is not clear, 
however, but we hypothesize that the neuroprotective 
properties of saffron or the action of saffron on retinal 
pigment epithelial (RPE) cells may play a role. Therefore, 
more extensive research at the cellular level is warranted 
to reveal the mechanism behind this phenomenon. In 
our study, objective improvement in visual acuity was 
not found in either the saffron or the placebo group, 
although patients in the saffron group frequently gave 
subjective reports of better vision as well as reports of 
increased general wellbeing. As a result, patients in this 
treatment group stated that they planned to continue 
taking the drug for longer periods. This may be related to 
the reported antidepressant properties of saffron. Since 
it has been shown that AMD is associated with 
depression (30% of patients with AMD are depressed), 
(32, 42)
 
saffron may serve a dual purpose in this patient 
population. Changes in the severity of AMD related to 
saffron supplementation at the end of the study period. 
We found that patients with a more advanced disease 
state received a greater benefit as evidenced by 
significant changes in ERG findings. However, these 
changes could not be proven statistically due to the small 
sample size. As such, future studies with a larger sample 
size are required. In conclusion, daily supplementation 
with 30 mg of saffron for 6 months was associated with 
statistically significant changes in macular OCT and ERG 
parameters in patients with both dry and wet AMD. 
Saffron supplementation may induce a mid-term, 
significant improvement in retinal function in AMD. The 
authors propose further research regarding saffron 
supplementation in clinical practice. 
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